Pharmacological Approaches to the Prevention of Restenosis After Coronary Angioplasty
- 1 January 1998
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 13 (4) , 291-301
- https://doi.org/10.2165/00002512-199813040-00005
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- ACE Polymorphism, a Genetic Predictor of Occlusion After Coronary AngioplastyThe American Journal of Cardiology, 1996
- Pharmacological Approaches to the Prevention of Restenosis Following AngioplastyDrugs, 1993
- Direct intraarterial wall injection of microparticles via a catheter: A potential drug delivery strategy following angioplastyAmerican Heart Journal, 1991
- An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.Journal of Clinical Investigation, 1990
- Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplastyAmerican Heart Journal, 1989
- Reduction in the Rate of Early Restenosis after Coronary Angioplasty by a Diet Supplemented with n–3 Fatty AcidsNew England Journal of Medicine, 1988
- Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary AngioplastyNew England Journal of Medicine, 1988
- Cardiovascular Effects of n-3 Fatty AcidsNew England Journal of Medicine, 1988
- Compensatory Enlargement of Human Atherosclerotic Coronary ArteriesNew England Journal of Medicine, 1987
- Effect of antiplatelet therapy on restenosis after experimental angioplastyThe American Journal of Cardiology, 1984